1 / 45

Overview of Screening Visit Procedures, Eligibility Criteria, and Visit Flow

Overview of Screening Visit Procedures, Eligibility Criteria, and Visit Flow. Screening Visit Procedures. What are 2 the primary goals of the screening visit procedures? Evaluate Eligibility Establish Baseline. Eligibility Criteria - Rationale. Rationale is to select participants who are

jfaucher
Download Presentation

Overview of Screening Visit Procedures, Eligibility Criteria, and Visit Flow

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Overview of Screening Visit Procedures, Eligibility Criteria, and Visit Flow

  2. Screening Visit Procedures • What are 2 the primary goals of the screening visit procedures? • Evaluate Eligibility • Establish Baseline

  3. Eligibility Criteria - Rationale Rationale is to select participants who are • Healthy but at risk for HIV infection • Likely to be retained • Likely to be adherent to product use plan • At low risk for safety issues potentially associated with product use

  4. Inclusion Criteria Protocol Page 23 • Age 18-45 • Able/willing to provide IC   • Adequate locator info • HIV-uninfected   • Sexually Active • Effective contraception use/intention • Agrees not to participate in other research studies

  5. Exclusion Criteria IVDU in past 12 months Gynecologic or genital procedure or pregnancy outcome w/in 90 days Participation other research study w/in 60 days Participation in VOICE/other PrEP studies w/in 12 months AST, ALT, or platelet count Grade 1 or higher Creatinine, hemoglobin, or pap result Grade 2 or higher IoR Discretion • Pregnancy intention or currently pregnant • Currently breastfeeding • Plans to relocate • Travel away for >8 weeks • Ongoing/untreated UTI • STI/RTI requiring treatment • ≥Grade 2 Pelvic Finding • Known adverse reaction to study product or latex • Chronic vaginal candidiasis • Uncontrolled chronic condition • PEP in past 6 months

  6. Exclusion Criteria Timeframes Screening Visit Timeline Non-therapeutic IV drug use > 4 episodes vag candidiasis -No Vaginal Intercourse 12 mos 6 months 90 days 60 days Screening Enrollment 28 days Ppt in VOICE or other PrEP studies -Ppt in Research involving meds/devices -Gyne/Genital Procedure -PregOutcome PEP Enrollment Visit Timeline

  7. Page 3 Components of Screening Visit • Administrative: • Screening IC • Assign PTID • Assess eligibility • Locator • Schedule Next Visit* • Reimbursement Clinical: • Medical/Menstrual Hx • Concomitant Meds • Contraceptive provision*† • Physical Exam • Pelvic Exam • Treatment or referral* Laboratory: • Urine: • Pregnancy • GC/CT • Urine culture*† • Pelvic: • Trichomonas • Herpes Lesion*† • Wet mount for candidiasis or BV*† • Pap Smear* • Vaginal pH • Gram stain • Endocervical swab • Behavioral: • HIV pre-/ post-test • HIV/STI risk reduction (offer condoms) • Contraceptive Laboratory: Blood: • HIV Serology • CBC with platelets • Serum Chemistries • Syphilis Serology • Questionnaires: • Demographics • Screening Behavioral Eligibility LoA#1

  8. Screening Window Enrollment Screening 28 Days If needed, screening visit procedures can be completed over multiple visits. One rescreen is allowed

  9. Page 39 Screening Visit Checklist

  10. ASPIRE Informed Consents Screening Enrollment • Off-Site Specimen Storage • IDIs/FGDs • LoA#2 • Subset • Spilhaus • Can defer to M1 • Long Term Optional

  11. Page 23 Screening Informed Consent

  12. Page 27 Informed Consent Tools • Fact Sheets (5 total) • IC Booklet • IC Tabletop Flip Chart • Ring Use Instructions/Important Information sheet • Pelvic model & sample ring

  13. Questions on Screening procedures?

  14. Screening VisitCASE REPORT FORMS

  15. Approach to ASPIRE CRF Training • Focus on purpose/reason for each CRF • Will try to address questions we received during the external review of the CRFs • Will not go item by item, but will practice form completion using scenarios • Will not review form instructions, but will refer to these as needed • CRFs can be found in your binder – Screening tab • Questions from all encouraged - Let’s get started!

  16. Page 49 Demographics (DEM-1) • Not interviewer-administered/translated • Collects required ppt descriptors (age, ethnicity) and descriptors requested for publications/reports • For drinks/week and cigarettes/day items, use estimates and rounding as needed – does not have to be exact • Cell phone & ‘income on her own’ questions used to describe participant SES • Question on travel time to the clinic used to assess ppt burden and may relate to retention • Items reflect participant information at the time of her SV only – not updated later unless correction is needed

  17. Page 51 Screening Behavioral Eligibility CRF • Ensures ppt behavioral eligibility items are asked and documented in the same way across sites and ppts • Interviewer-administered; in local language(s) • Practice before administering for 1st time • Read items aloud as they appear • provide clarification as needed • Complete all form items even if ppt provides response that indicates she is not eligible • Note item 17 includes IPM 027 participation • Will be clarified in a Data Communique • Review closely once completed to ensure all items are completed as needed • Reference form when completing matching items on Eligibility Checklist

  18. Page 55 Screening Menstrual History (SMH-1) • Created to help sites document items relevant to a ppt’s baseline menstrual history and bleeding pattern • Is DataFax – data will go into the study database • Items 3-7: complete based on the ppt’s usual menstrual periods as experienced prior to the SV • if ppt is amenorrheic (consistently or partially), complete items based on the how the ppt describes her most recently-experience menstrual periods and provide additional details as needed in item 8. • If the participant reports more than 99 days between her usual menses, record “99” for item 3 (maximum boxes) and provide more details in item 8

  19. Page 55 SMH-1 continued… • Item 6 (last menses day) – mark “ongoing” if on menses at SV; do not need to update at EV • Item 8 • Describe as best as possible participant’s baseline bleeding pattern and associated symptoms • Update as needed at EV if bleeding pattern or symptoms changes (Ex. due to new HC method) • Per note at bottom, update PRE CRF as needed with baseline irregular bleeding/menstrual symptoms

  20. Page 57 Screening Visit Physical Exam (SPX-1) • DataFax form • All items require a response – all systems listed in ‘Findings’ portion of the form required to be evaluated • Use Notes line to describe abnormal findings • Option to use notes line to describe normal findings as well (ex. normally healed scar) • Make sure Staff Initials/Date are in order if one person does vitals and a separate person does the exam assessments (use brackets as needed) • Record medically-relevant findings onto PRE CRF (per previous presentation)

  21. Page 59 Pelvic Exam Diagram (non-DataFax) • Used as the source document for all normal and abnormal pelvic exam findings • When completing, keep in mind that someone else may look at this form prior to the participant’s next pelvic exam. Be descriptive! • Record all abnormal findings on the Screening Pelvic Exam CRF (diagrams form is source)

  22. Page 61 Screening Pelvic Exam (SPE-1) • Completed at SV to all abnormal pelvic exam findings observed • Columns arranged by location with a general ‘other’ column • Lists abnormalities using terms in FGGT and CONRAD manual • Record abnormal findings on PRE CRF per note below items 1b, including location • If a 2nd (repeat) screening pelvic exam performed, complete new SPE-1 and PE Diagrams; fax repeat SPE-1 only once enrolled

  23. Page 63 Pre-existing Conditions Log (PRE) • Used to document in one place each participant’s baseline medical/menstrual history • Will include ppt-reported conditions as well as abnormalities captured on: • Pelvic Exam Diagrams, Screening Pelvic Exam CRFs • Screening and Enrollment Physical Exam CRFs • Grade 1 and higher laboratory results on Screening Lab Results CRF • Newly-diagnosed (at SV) STIs per Screening STI Test Results CRF

  24. Pre-existing Conditions CRF – con’t • Page number – start with 01, go up as needed • Condition • Follow guidelines for AE text except do record past surgeries as needed • Be as descriptive as possible • Onset Date (Month and Year) • If uncertain, use best estimate; year required • Comments • Add info on frequency and duration of chronic condition outbreaks; other relevant info for the “snapshot”

  25. Pre-existing Conditions CRF – con’t • Ongoing at Enrollment? • Leave blank at SV if ongoing; complete at EV • Chronic/recurrent diagnoses are ongoing • Severity Grade • Assess per Tox Table and FGGT • Mark “not gradable” if condition is below Grade 1 or resolved at time of report (ex. C-section entry) • At Enrollment Visit: • If condition has resolved, do not update severity grade • If severity grade has or on or prior to EV, update as needed • Review all PRE CRF pages at SV and EV to ensure a complete medical history (including current conditions) is created • Info may be needed for Clinical Queries or auditors months or years after originally-recorded

  26. Pre-existing Conditions CRF – con’t • Entries can be added and modified post-enrollment • Ppt may have forgotten to report a symptom • Perhaps something that was thought to be not relevant is later considered relevant; if so, add to PRE • May need to collapse signs/symptoms into a diagnosis • Write a chart note to explain why an entry is being added/modified during follow-up • Document meds taken for PRE on Concomitant Medications Log CRF

  27. Page 65 Concomitant Medications Log (CM-1) • Completed starting at the SV; updated as needed at EV and during follow-up • Record trade name whenever possible; if not, use generic name • For injectable contraceptives, record separate entry for each injection • For OCPs, record one entry for each pill pack • For all other injectable treatments, document single entry for tx. • If exact dose/units not known, put best description possible • “Taken for AE” item will always be ‘no’ for entries at SV • For each contraceptive entry, record a response for “If contraceptive, was it dispensed at research center?” • Update PRE CRF if CM completion reveals conditions not already reported or observed

  28. Page 67 Screening Specimen Storage (SSS-1) • Documents collection of the 2 SV stored specimens • Vaginal Smear for gram stain • Endocervical swab • Blood visible on swab?: used to inform swab analyses done at Network Lab • Mark specimens as “stored” if collected and sent for storage; update if you find out later that specimens were not stored • Also collects results of syphilis testing • Complete only 1 CRF for each participant per screening attempt • Will not collect specimens for storage or complete form if a repeat 2nd pelvic exam is done

  29. Page 69 Screening Visit LDMS Tracking Sheet Optional Note Visit Code of SV is pre-printed = 97.0

  30. Page 71 Screening Laboratory Results (SLR-1) • Complete CRF as SV results become available • If severity grade box present, assess for severity grade per Tox Table • If below grade 1, leave box blank • If Grade 1 or higher, add to Pre-existing Conditions form • Notes on eligibility are present when applicable • If some or all tests are repeated prior to randomization: • Complete a new SLR • Only fax 2nd SLR CRF completed, once ppt enrolls OR • Use Alternate Collection Date if not all results on CRF repeated

  31. Page 71 Screening Laboratory Results (SLR-1) Using alternate collection date to update partial lab results

  32. Page ?? Screening STI Test Results (SST-1) • Captures results of Trich, GC, CT tests done at SVA • Will also capture wet mount results, if done • If any STIs diagnosed, record on PRE CRF • Will allow us to report on how many ppts had STIs prior to enrollment • Vaginal fluid pH assessed only if clinically indicated

  33. Page 73 Eligibility Criteria (ECI-1) • Allows SCHARP to report on # ppts screened, # enrolled, # screen fails and reasons for screen fails • Item 3: • “participant did not complete all screening procedures” – ppt was eligible but did not complete all screening procedures (including EV) • “Eligible but declined enrollment” – participant was eligible but she chose not to enroll • “Not eligible” –ppt completed procedures as planned but does not meet all eligibility criteria • Item 4: Mark all reasons that apply • 4g: Mark if ppt participant in VOICE or other HIV prevention trial using antiretroviral medication in the past 12 months • Included in the SV form packet; complete only if screen fail • Move to EV packet and complete then if EV scheduled

  34. Screening Visit QA/QC • Before ppt leaves: • Review visit checklist for completeness • Review Screening Behavioral Eligibility Criteria form for completeness • Make sure lab requisition docs/LDMS Sheet and lab specimens are in order • Review pelvic exam/physical exam forms and make sure all needed items are on PRE • Make sure you have a way to be alerted once local lab results come back (or don’t come back) • Complete SLR, SST, PRE as needed, Eligibility Checklist as needed • Do not fax any forms until ppt enrolls; fax ECI if ppt will not proceed to EV • Make sure systems are in place for EV, including scheduling, ppt files, Pharmacy is aware of potential EV, etc.

  35. DataFax Overview Video – Atlas

  36. Additional Tools

  37. Page 75 Eligibility Checklist

  38. Page 81 PTID Name Linkage Log

  39. Page 83 Screening Enrollment Screening Screen Fail

  40. Documentation for Screen Failures • Save IC forms (IC/coversheet). • Document reasons for ineligibility and date of determination as per the Eligibility Checklist • ECI-1 CRF – complete and fax to SCHARP (do not fax any other CRFs for the ppt). • Document necessary referrals in ppt’s file; document that clinically significant abnormalities were communicated to ppt (Ex. Grade 3 lab value) • Make sure all SD is complete up until the time that ineligibility was determined, including SV Checklist • File all documents per MTN Data Management SOP

  41. Page 85 Last Day to Enroll Calculator

  42. Additional Tools • Participant Tracking Database • Coenrollment database/system

  43. Activity

  44. Screening Visit Activity • Pair up with the person sitting next to you • Everyone will receive a screening packet of CRFs/source documents. This participant has completed her screening visit, and all labs are currently pending. • Complete the screening visit column on the Eligibility Checklist in your training binders to evaluate/document her eligibility thus far.

  45. Screening Visit References • Eligibility criteria protocol Sections 5.2/ 5.3 • Screening procedures protocol Section 7.2 • Accrual SSP Sections 4.2.1 – 4.3.4 • Visit Checklist Templates SSP Section 7

More Related